Related Experiment Video
Updated: Aug 8, 2026
12:18
LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
Published on: February 1, 2020
LHX6 is a sensitive methylation marker in head and neck carcinomas
M R H Estécio1, E M Youssef, P Rahal
1Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX, USA.
Oncogene
|May 30, 2006
Summary
Researchers identified a new molecular marker, DIME-6 hypermethylation, for head and neck squamous cell carcinoma (HNSCC). This epigenetic marker shows high prevalence in HNSCC and other cancers, offering potential for improved diagnostics.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Head and neck cancer is a significant cause of mortality with limited effective molecular markers.
- Identifying novel biomarkers is crucial for improving diagnosis and treatment of head and neck squamous cell carcinoma (HNSCC).
Purpose of the Study:
- To discover new molecular markers for head and neck squamous cell carcinoma (HNSCC).
- To investigate the role of epigenetic dysregulation, specifically DNA methylation, in HNSCC development.
Main Methods:
- Utilized methylation-sensitive arbitrarily primed PCR (MS/AP-PCR) to identify differentially methylated sequences in HNSCC.
- Employed combined bisulfite restriction analysis (COBRA) to validate hypermethylation of the identified marker.
- Analyzed methylation patterns in HNSCC cell lines, primary tumors, and normal oral mucosa samples.
Main Results:
- A frequently hypermethylated fragment, mapping near a CpG island on chromosome 9q33.2, was identified and termed DIME-6.
- Hypermethylation of DIME-6 was associated with transcriptional silencing of an alternative LHX6 gene transcript.
- DIME-6 hypermethylation was detected in 92.8% of HNSCC cell lines and 65.6% of primary HNSCC tumors.
- Significant hypermethylation was also observed in cell lines and primary tumors from colon, breast, leukemia, and lung cancers.
Conclusions:
- Differentially methylated (DIME)-6 hypermethylation serves as a promising cancer marker for HNSCC.
- The findings highlight the potential of DIME-6 as a pan-cancer biomarker across various neoplasias.
- This study underscores the importance of exploring epigenetic dysregulation for novel cancer marker discovery.
Related Concept Videos
03:18Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...